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In current study, immediate release solid dispersion (SD) formulation of antiulcer drug
lafutidine (LAFT) was developed using hot melt extrusion (HME) technique. Amphiphilic
Soluplus used as a primary solubilizing agent, with different concentrations of selected
surfactants like PEG 400, Lutrol F127 (LF127), Lutrol F68 (LF68) were used to investigate their
influence on formulations processing via HME. Prepared amorphous glassy solid dispersion
was found to be thermodynamically and physicochemically stable. On the contrary, traces
of crystalline LAFT not observed in the extrudates according to differential scanning
calorimetry (DSC), X-ray diffraction (XRD), scanning electron microscopy (SEM) and Raman
spectroscopy. Raman micro spectrometry had the lowest detection limit of LAFT crystals
compared with XRD and DSC. Atomic Force microscopy (AFM) studies revealed drug-
polymer molecular miscibility and surface interaction at micro level. 1HeCOSY NMR
spectroscopy confirmed miscibility and interaction between LAFT and Soluplus, with
chemical shift drifting and line broadening. MD simulation studies using computational
modelling showed intermolecular interaction between molecules. Dissolution rate and
solubility of LAFT was enhanced remarkably in developed SD systems. Optimized ratio of
polymer and surfactants played crucial role in dissolution rate enhancement of LAFT SD.
The obtained results suggested that developed LAFT has promising potential for oral de-
livery and might be an efficacious approach for enhancing the therapeutic potential of
LAFT.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved., þ91 22 3361 2222; fax: þ
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Pharmaceutical drug development research using hot melt
extrusion (HME) has attracted increasing attention as novel
strategy to produce delivery system with enhanced bioavail-
ability as well as solubility of dissolution rate limited APIs
[1e3]. This technology employs the application of high shear
and high temperature to formulate drug-polymer molecularly
dispersed systems, can be termed as solid dispersions (SD) or
solid solutions [4]. HME is an industrially scalable continuous
manufacturing technique without the necessities of addi-
tional drying or process fragments [5]. The distinctiveness of
the procedural features allows the fabrication of various drug
delivery systems. HME technology has many advantages over
traditional processing techniques such as spray drying or co-
evaporation, which involves organic solvents [6]. Homoge-
neous mono-phase systems with the drug molecularly
dispersed in the polymer matrix, is challenging delivery, as
such systems are intrinsicallymetastable [7]. The formation of
melt extrusion involves the exchange of heat energy during
HME process and followed by instant cooling of the melt
which affects thermodynamic and kinetic properties of
forming solid dispersion variance [8]. Use of highly water
soluble carrier in solid dispersion always increases the chan-
ces of crystallization due to swelling behavior when comes in
contact with the aqueous GI fluid [9]. Therefore, surface active
agents or surfactants used as inhibitors for recrystallization.
HME has the unique property to maintain the amorphous
state of the drug after the formation of solid dispersion.
Literature cited various methods for preparing amorphous
solid dispersion such as melt method, solvent evaporation,
cyclodextrin inclusion complex, cryo milling which explained
the importance of solid dispersion type of formulation strat-
egy [10].
Lafutidine (LAFT) a newlydevelopedhistamineH2-receptor
antagonist, inhibits daytime (i.e., postprandial) as well as
nighttime gastric acid secretion in clinical studies. It is practi-
cally insoluble inwater and has low bioavailability. LAFT has a
very low aqueous solubility, which impairs its dissolution in
upper gastric fluid producing problems to prepared systems
[11]. Overall, these characteristics hinder its therapeutic
application by delaying the absorption rate and thereby onset
of action or activity [12]. Together solubility, permeability and
dissolution rate of a drug are essential factors for determining
itsoralbioavailability [13]. Literature reportsgenerally revealed
the fact that drugmaterials with a very low aqueous solubility
will show dissolution rate limited absorption and hence poor
bioavailability. Improvement of aqueous solubility in such a
case is a valuable assignment to improve therapeutic efficacy
[14]. However there is no literature on the enhancement of
solubility of LAFT by hot melt extrusion method reported.
Subsequently there is a need to deliver LAFT in formulation
with increased solubility and improved dissolution profile.
For the current study we selected polyvinyl capro-
lactamepolyvinyl acetateepolyethylene glycol graft copol-
ymer (Soluplus) a novel polymer with amphiphilic properties
and explored its solubilizing potential using HME technology.
Soluplus has been especially developed for hot melt extru-
sion process. It offers exceptional capabilities forsolubilization of BCS class II and class IV drugs, with the
extensive possibility of making SD by hot-melt extrusion [15].
Its bulk density is low and has high molecular weight with
excellent flow properties. The prime objective was to prepare
stable SD systems of low Tg and water insoluble drug LAFT
using an optimized ratio of drug-polymer-surfactant blends
[16]. The next part involves physicochemical characterization
using various analytical techniques to understand the
drugepolymer molecular interactions. Six-month stability
according to the ICH guideline studies was performed and
supported by DSC, XRD, dissolution studies.2. Materials and methods
2.1. Materials
LAFTwas obtained as a generous gift fromAlkem Laboratories
Ltd., India. Soluplus, a hydrophilic graft copolymer of poly-
vinyl caprolactamepolyvinyl acetateepolyethylene, Lutrol
F127 and Lutrol F68 were kindly donated by BASF Corporation,
Mumbai, India (Head office Ludwigshafen, Germany). PEG 400
of analytical grade was procured from Sd. Fine Chemicals,
Mumbai, India. All other chemicals used were of analytical
grade or equivalent quality.
2.2. Methods
Calculation of solubility parameter (d), glass transition tem-
perature (Tg) and FloryeHuggins parameter (c).
As an indicator of the drug-polymer miscibility, values of
d were calculated using the Hoftyzer and vanKrevelen group
contribution method described by the following Eq. [17].
d2 ¼ d2d þ d2p þ d2h (1)
where,
dd ¼
X
Fdi=V; dp ¼
X
F2pi
1=2
=V; dh ¼
X
Ehi=V
1=2
Here i is the groups within the molecule, d is the total sol-
ubility parameter, dd is the contribution from dispersion
forces, dp is the contribution from polar interactions, dH is the
contribution of hydrogen bonding, Fdi is the molar attraction
constant due to molar dispersion forces, Fpi is the molar
attraction constant due to molar polarization forces, Ehi is the
hydrogen bonding energy and V is the molar volume. The
solubility parameters of polymer and surfactant combinations
were calculated using the following Eq.
d1;2 ¼ Vf1d1 þ Vf2dr2 (2)
where Vf is the volume fraction of each compound.
Miscibility of the drug with the polymer can be assessed
based upon the shift inmelting endotherm or Tg of the drug or
can be predicted theoretically using the GordoneTaylor
equation based on the Tg, densities, and weight fractions of
the components.
Tgmix ðHME systemÞ ¼ w1Tg1 þ kw2Tg2=w1 þ kw2 (3)
KzTg1r1=Tg2r2 (4)
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W2 are the weight fractions of the components, and K is the
parameter calculated from the true densities (r1 of drug and r2
of polymer) and Tg2 of the amorphous components [18]. The
true density measurement of the LAFT and Soluplus were
determined in duplicate using a gas displacement pycnometer
(Accupyc 1330; Micromeritics, Norcross, Georgia).
The FloryeHuggins (FH) interaction parameter (c) was
calculated using the following equation:
1
Tmmix
 1
Tmpure
¼ R=DHf
n
lnFdrug þ ð1 1=mÞFpolymer
þ cF2polymer
o
(5)
where, Tm mix is the melting temperature of the drug in the
presence of the polymer, Tm pure is the melting temperature
of the drug in the absence of the polymer, DHf is the heat of
fusion of the pure drug, m is the ratio of the volume of the
polymer to LAFT, and F drug and F polymer are the volume
fractions of the drug and the polymer, respectively [19].2.3. Preparation of hot melt extruded solid dispersion
Single screw extruder system was used for the hot melt
extrusion process manufactured by S.B. Panchal, Mumbai. A
die with 2 mm bore diameter was selected based on the pre-
screening of different dies to obtain uniform extrudes. LAFT
and Soluplus in 1:1 ratio for the batch size of 30 g mixed
together usingmortar pestle for 4e5min. After that, this blend
mixture was poured through the hopper on the rotating screw
with constant feeding rate; with screw speed of 50 rpm. The
extruder temperature was set at 84 C initially (optimized
early). The mixture takes about 3 min to form molten mass
betweenwalls of the screwandextruderbarrel. Residence time
was about 15e20 min for LAFT-Soluplusmixture blends. The
similar procedure with different batch size was employed for
further drug: polymer combinations (e.g. 1:3, 1:5, 1:7, and 1:9)
with different temperature parameters as shown in Table 1.
Themelt extrudatesweregrindedandpassed througha200mmTable 1 e Different parameters, ratio of drug to polymer to sur
Lafutidine- LAFT, Soluplus e SOL, Polyethylene Glycol 400 e
Formulation
codes
Formulation
composition
Ratio of
drug and
excipient (%)
Extrusion te
(speed- 50 rp
LF1 LAFT:SOL:PEG400 1:0.8:0.2 82e84
LF2 LAFT:SOL:PEG400 1:1.8:0.2 82e84
LF3 LAFT:SOL:PEG400 1:2.8:0.2 82e84
LF4 LAFT:SOL:LF127 1:0.8:0.2 75e77
LF5 LAFT:SOL:LF127 1:1.8:0.2 75e77
LF6 LAFT:SOL:LF127 1:2.8:0.2 75e77
LF7 LAFT:SOL:LF68 1:0.8:0.2 80e82
LF8 LAFT:SOL:LF68 1:1.8:0.2 80e82
LF9 LAFT:SOL:LF68 1:2.8:0.2 80e82
LF10 LAFT:SOL 1:1 85e87
LF11 LAFT:SOL 1:3 85e87
LF12 LAFT:SOL 1:5 85e87
LF13 LAFT:SOL 1:7 85e87
LF14 LAFT:SOL 1:9 85e87
LAFT e e esieve. Use of different surfactants such as PEG400, Lutrol F127
and Lutrol F68 overall 14 optimized formulation batches (LF1 to
LF14) were practically carried out. In this paper the SD having
highest (i.e. 50%) drug loading are discussed in terms of phys-
icochemical and dissolution rate characterisation [20].
2.4. Physical state characterization
2.4.1. Differential scanning calorimetry (DSC) and modulated
differential scanning calorimetry (M-DSC)
Differential scanning calorimeter (DSC-PYRIS-1, Perkin Elmer,
USA) was used to study the drug, polymer and SD crystalline
variability. Pure LAFT, Soluplus, Lutrol F127, Lutrol F68 and
SD (i.e. 4e5 mg) were accurately crimped in aluminium pans
and heated at an increment of 10 C/min under a nitrogen
purge (20 ml/min) from 0 C to 160 C. During M-DSC accu-
rately weighed samples (4e5 mg) were placed in sealed
aluminum pans and a heat-cool-heat cycle applied involving
heating from 40 to 260 C at 10 C/min then rapidly cooling to
40 C and then reheating to 260 C at 10 C/min. Both the ex-
periments were performed in a pure dry nitrogen atmosphere
using same instrument [21].
2.4.2. Powder X-ray diffractometry
X-ray diffraction pattern were obtained by ADVANCE D8 sys-
temwith CuKa radiation (Bruker, USA). The recording spectral
range was set at 0e40 (2q) using the Cu-target X-ray tube and
Xe-filled detector. The voltage 40 kV with current 20 mA was
set. The samples were placed in a zero background sample
holder and incorporated on a spinner stage. CueK001 radiation
was used as an X-ray source. Soller slits (0.04 rad) were used in
the incident and diffracted beam path [22].
2.4.3. FT-IR spectroscopy
Pure LAFT and SD were analysed by using a Fourier transform
infrared spectrophotometer model 4100 (Spectrum GX-FT-IR,
Perkin Elmer, USA). Samples were mixed with dry potassium
bromide (dried initially) using a mortar and pestle, com-
pressed to prepare a disk and analyzed over a rangefactant and release rate of prepared SD. (Abbreviation:
PEG 400, Lutrol F127 e LF127, Lutrol F68 e LF68).
mp. (C)
m for all)
Batch
size (g)
Residence time
(min)
Drug release (%)
20 min 60 min
30 8e10 83.83 100.3
30 8e10 85.91 103.01
40 8e9 99.67 106.77
25 10e12 103.43 108.1
30 10e12 104.05 110.1
30 10e12 79.45 114.27
40 12e14 81.95 89.46
30 12e14 89.46 99.88
30 12e14 64.69 103.01
30 18e20 72.98 84.69
30 18e20 79.45 88.58
30 15e17 81.95 94.56
40 13e15 89.46 99.88
40 11e13 94.37 103.01
e e 4.37 8.75
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 9 2e1 0 6 954000e400 cm1. Infrared transform analysis was performed
on samples and spectra were generated [23].
2.4.4. Scanning electron microscopy (SEM)
The shape and surface morphology of the LAFT powder and
LAFT-loaded solid dispersion were examined using XL 30
Model JEOL 6800 scanning electron microscope made in Japan
during analysis. Double-sided carbon tape was affixed on
aluminium stubs over which powder sample of LAFT and
prepared SD was sprinkled. The radiation of platinum plasma
beam using JFC-1600 auto fine coater was targeted on
aluminium stubs for its coating to make layer of 2 nm thick-
ness above the sprinkled powder for 25 min. Then, those
samples were observed for morphological characterization
using a gaseous secondary electron detector (working pres-
sure: 0.8 Torr, acceleration voltage: 10e30.00 kV).
2.4.5. Raman spectroscopic analyses
The Raman spectra of the SD were recorded with a Lab-
RamHR800 (Horiba Jovan Yvon) equipped with a 633-nm
AreNe laser [24]. The laser excitation was focused using a 50
objective (OLYMPAS Corporation) and the scattered light was
totally transmitted through the notch filter towards the
confocal hole and entrance slit of the spectrograph. The
stokes-shifted Raman scatter was dispersed using 1800
groove/min grating onto a peltier-cooled changed-coupled
device (CCD, Andor Technology PLC) to capture a spectrum.
The spectra of SD were recorded more than once and repro-
ducible results were obtained. Raman mapping or imaging of
LF4 SD was carried out to understand the drug distribution
inside polymer matrix.
2.4.6. Preparation of extrudates for AFM characterisation
JXA-8530F Hyper Probe Electron Probe Micro-analyzer instru-
ment by JEOL was employed for AFM analyses. Freshly frac-
tured extrudates onmicroscopic glass slidesweremounted on
the micrometre positioning stage of a Dimension Icon AFM
with accelerating voltage of 1e30 kV. Probe current range kept
between 10 pA and 200 pA and back scattered electron images
were obtained. Obtained images were scanned for maximum
resolution and magnification to generate best microscopic
images [25].
2.4.7. Molecular modelling interaction studies
The monomer unit structures of Soluplus, Lutrol F127, Lutrol
F68 and LAFTwere constructed by using Gaussian programme
in Schrodinger, maestro software programme, USA. The
energy minimization, docking and MD-simulation studies of
different conformations of drug-polymer were run toTable 2 e Shows the GordoneTaylor equation calculated Tgmix o
experimental HME processing temperature for relevant system
Form. codes W1 Tg1 W1
*Tg1
w2 Tg2 W2
*Tg2
p1
LF1 0.5 101 50.5 2 82 164 1.254
LF4 0.5 101 50.5 2 75 150 1.254
LF7 0.5 101 50.5 2 80 160 1.254
LF10 0.5 101 101 1 85 85 1.254understand the structural interaction and to identify most
stable conformation of drug with polymer [26,27].
2.4.8. 1He COSY NMR analyses
1He COSY NMR experiments were carried out on prepared SD
(LF4) powder using a Varian Mercury Plus 300 NMR spec-
trometer operated at 300 MHz with cross polarization contact
time of 1 ms, pulse repeat time of 1 s, accumulation of 1000
scans, and high-power 1H-decoupling of 100 kHz during signal
acquisition with a 80 to 130 with suitable solvent [28]. Suf-
ficient SD powder sample was dissolved in solvent DMSO and
then used for analysis. Sample was spun at a rate of 5 kHz at
magic angle with 2D width 4807.7 Hz. 5 mmmulti nuclear CP-
MAS probe for solids application was used. Data processing
was carried out using sine bell software with FT size
2048  2048 and for total time of 65 min.
2.5. HPLC Analyses
LAFT and SD content were determined using a Binary HPLC
pump, and 2998 UV Array detector (Agilent Corporation, Mil-
ford, Massachusetts) Binary HPLC pump, and 2998 UV Array
detector (Agilent Corporation, Milford, Massachusetts) and
mixture 0.02 M dihydrogen potassium ortho phosphate and
0.02M dipotassiumhydrogen orthomonophosphate (1:1 ratio)
with acetonitrile in the ratio of 30:70 adjusted to pH-6 was
used as mobile phase. The injection volume was 20 ml and
detection was at 215 nm for LAFT and SD [29].
2.6. In vitro dissolution studies
Quantity equivalent to 10 mg of LAFT was weighed and filled
inside hard gelatine capsules and were used for the dissolu-
tion studies further. The LAFT SD and marketed tablets
Lafumec were investigated for their dissolution behavior, in
the 900 ml 0.1 N HCl of pH 1.2 as dissolution medium at
37  0.2 C using a USP dissolution apparatus I (Electrolab-
DBK, Mumbai, India) at speed of 100 rpm [30]. LAFT released
from the SD and Lafumec, characterised by UV absorbance
measurement at a wavelength of 286 nm.
2.7. Stability of prepared SD
Prepared SD were kept inside the closed glass vials under
controlled temperature environment inside stability chamber
(Thermo Lab, India) with relative humidity of (35%, 60%, 75%)
RH and temperature (37 C, 40 C, 60 C) for stability studies.
Samples were removed after 1, 3 and 6 months, evaluated for
dissolution rate study and compared with those SD testedf SD systems, which are similar (or range of ±5 C) to that of
s.
p2 Tg1
*p1
Tg2
*p2
k W1*Tg1þ
k W2*Tg2
w1
þkw2
T Mix
1.3 126.6 106.6 1.18 245.35 2.87 85.3029
1.3 126.6 97.5 1.29 245.35 3.09 79.1962
1.3 126.6 104 1.21 245.35 2.93 83.5767
1.3 126.6 110.5 1.14 198.43 2.14 92.4551
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Fig. 1 e DSC thermograms of LAFT and SD systems.
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SD was evaluated using HPLC at l ¼ 215 nm.3. Results and discussion
3.1. Drugepolymer solubility parameter (d)
It is normally believed that drugepolymer miscibility and
phase uniformity at interface depends upon the difference in
d values (Dd) between two components. If Dd is less than
7MPa1/2 both components are miscible. When Dd value was
10MPa1/2, incompatibility and phase separation between drug-
polymer occurs. The solubility parameter for drug and poly-
mer used was calculated using group contribution method
(data not shown). The d of SOL, PEG400, LF127 and LF68 are
similar and are close to the reported data. The Dd values be-
tween LAFT-Soluplus and LAFT-Soluplus-surfactant blends
were in the range 2.89e5.6 MPa1/2, being less than 7 MPa1/2
indicates likely miscibility. However, the combinations of SOL
with PEG400 or LF127 or LF68 appear not to increase the Dd
between LAFT and polymer mixtures, which suggest misci-
bility enhancement. The Tg value of SOL is 72 C. After
comparing a series of ratios according to the dispersion state
of LAFT and the uniformity of extrudates, drug to polymer
ratios were finally chosen as themost favourable carriers. The
results suggest that Dd and DTg are useful parameters in pre-
dicting miscibility and polymer selection [32].3.2. GordoneTaylor analysis
Thermal analysis by DSC is the key feature to understand
drugepolymer miscibility for the stability of amorphous drug
in solid dispersion systems. Incomplete miscibility or reduced
solubility can result in the formation of concentrated drug
spheres that may lead to recrystallization after production
and during stability [33]. The Soluplus showed a Tg of 72 C
and of LAFT is 101.97 C. A single Tg was observed for all the
ratios of drugepolymer binary mixtures. According to the
GordoneTaylor equation, if the drug and polymer are
Fig. 2 e M-DSC thermograms of SD systems.
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ranges between the Tg of the pure components and is
dependent on the relative proportion of each component
shown in Table 2. From the results obtained theoretically by
GordoneTaylor analysis found to be in the similar range of Tg.
3.3. Flory-Huggins (FH) modelling
FH modelling suggests that if c  0.5/M, then there are
slightest amount of unfavourable interactions between the
drug, polymer and excipient mixture, which may cause phase
separation. From the results, calculated value of FH interac-
tion factor (c) is not 0.5/M which signifies higher favorable
extent of drug-polymer interactions at micro level. This is
happened due to reduction of entropy during formation of
solid dispersion using HME and also indicates thermodynamic
stability of developed SD [34]. Adhesive interaction between
drug and polymer favoured by the reduction in the Tg of SD
systems, which implicates themiscibility of drug and polymer
shown in Table 3.
3.4. Solid state characterization
3.4.1. Thermal investigation using DSC and MDSC
Solid-state extruded SD was analyzed using DSC and MDSC.
DSC was used to determine the LAFT state in the extruded SD
and to identify possible drugepolymer interactions. Fig. 1 de-
picts the thermograms of pure LAFT, which clearly show
endothermic sharp peak at 101.97 C respectively. The ther-
mograms of the hot melt extrudates SD showed different
thermal behavior for LAFT. As shown in Fig. 1 the drugmelting
endotherms disappeared completely. The absence of LAFT
endotherms suggests either drug solubilization due to the
presence of used excipients or being present in an amorphous
state. Thus, it was concluded that LAFT converted to its
amorphous form during hotmelt processing approach used to
produce thesoliddispersions.MT-DSCstudieswereperformed
to recognize the stablenatureof amorphous solid dispersion of
LAFTprepared byHME. Compared to the sharpmelting peak of
pure LAFT, the endothermic peaks in SD broadened during the
first heating cycle and then disappeared in the second heating
cycle. This is caused by gradual dissolution of the crystallinedrug in the molten polymers and complete conversion to the
amorphous stateduring theDSCheatingprocess.MDSCshows
the respective Tg of SD prepared approximately in similar
range of temperature which signifies the amorphous drug na-
ture in SD Fig. 2. The physical state of LAFT was further
investigated by employing X-ray powder diffraction. The SD
prepared after HME convert drug into amorphous stable state.
3.4.2. XRD Analyses
XRD of LAFT consist of sharp multiple peaks, indicating the
crystalline nature of the drug with specific % crystallinity. In
the XRD of LAFT peak intensities observed at (10.23, 12.82,
13.12, 15.14, 17.81, 18.12, 19.24, 21.52, 22.34, 23.45, 24.44, 25.62,
27.12, 28.22, 31.88, 41.91, 46.43). Characteristic peaks in-
tensities of LAFT observed at 8000, 7000, 5500, 5300 and 4300.
In the case of SD (about 2 g) when exposed to X-ray beam,
shows disappearance of most of the crystalline endothermic
peak and characteristic intensities of LAFT. This indicates
complete transformation of crystalline LAFT into amorphous
form during HME process. From the XRD studies of both fresh
and aged SD systems amorphous nature of LAFT after HME is
confirmed. The observed few intensity peaks in the dif-
fractograms are attributed to the tablet excipients such as
PEG400, Lutrol F127 and Lutrol F68 as shown in Fig. 3. The
diffractograms indicate that LAFT is in amorphous state (or
molecularly dispersed) in the solid dispersions. The XRD re-
sults are in good agreement with those of DSC thermograms.
3.4.3. FTIR Analyses
Possible interactions between drug and polymer in SD were
investigated by FTIR. FTIR spectra of LAFT and SD were
examined. FTIR spectrums are properly labelled and shown in
(Fig. 4A). IR of pure LAFT characteristic sharp peaks of alkene
stretching (aCeH and CH2) vibration at 3324.32e3016.48 cm
1
and alkane stretching (eCH3, eCH2 and eCH) vibration at
2853.73 cm1. Also exhibited CaO stretch at 1738.2 cm1 due to
saturated ketone and CaOeNH stretching at 1635.90 cm1. A
selective stretching vibration at 1561.57 cm1 and
1525.80 cm1 for primary and secondary amine was also
observed. For functional groups like SaO stretch and eCeS
stretch showed vibrations at 1041.78 cm1 and 729.57 cm1
respectively. Most of the peaks are observed in the spectral
Fig. 3 e XRD patterns of pure LAFT, LF1, LF4, LF7 and LF10 SD for fresh and aged systems.
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due to stretching (bendingaCeH andaCH2),eCHdeformation
and eCH bending. In the IR spectra of LF1 showed character-
istic peaks at 3385.48 cm1, 1737.1 cm1, 1602.19 cm1,
1384.67 cm1, 1078.46 cm1, 841.65 cm1 and 714.02 cm1. In
the IR spectra of LF4 showed characteristic peaks at
3408.99 cm1, 1736.36 cm1, 1607.10 cm1, 1384.41 cm1,
1238.92 cm1, 1111.13 cm1, 973.04 cm1, 841.33 cm1,
715.52 cm1 and 604.15 cm1. In the IR spectra of LF7 showed
characteristic peaks at 3400.80 cm1, 1731.75 cm1,
1598.90 cm1, 1384.73 cm1, 1110.72 cm1, 841.16 cm1,
789.56 cm1, 713.49 cm1 and 608.48 cm1. In the IR spectra of
LF10 showed characteristic peaks at 2913.25 cm1,
2352.62 cm1, 1731 cm1, 1614.15 cm1, 1555.85 cm1,
1445.07 cm1, 1123.38 cm1, 841.98 cm1, 716.78 cm1,
604.86 cm1 and 514.30 cm1. The IR spectra of SD signify the
presence of drug and no change in its functional properties.
An IR spectrum of Soluplus represents two characteristicpeaks at 2913 cm1 and 1612.39 cm1. While IR spectrum of
unprocessed Lutrol F127 and Lutrol F68 showed characteristic
peaks at 2870.19 cm1, 1975.36 cm1, 1590.27 cm1,
1466.88 cm1, 1343.65 cm1, 1112.01 cm1, 962.69 cm1,
841.98 cm1, 528.39 cm1 and 2884.01 cm1, 1966.16 cm1,
1592.16 cm1, 1466.26 cm1, 1343.62 cm1, 1121.69 cm1,
963.15 cm1, 842.63 cm1, 528.95 cm1 respectively. The
addition of polymer and surfactant during HME process would
not affected LAFT molecule stretching vibrations. Interaction
between the polymer and drug in SD mixtures formed mo-
lecular dispersions with slight shifting of specific intensities
compared to pure LAFT IR spectrum. Free hydrogen atoms
forms hydrogen bonds with LAFT in the SD possibly. The
carbonyl group is more favourable for hydrogen bonding and
intermolecular interactions than the nitrogen atom because
of steric hindrance. For SD, the eOH stretching bands broad-
ened and the intensity of the bands decreased to minimal,
indicating specific degree of interaction between the proton
Fig. 4 e A. Infrared spectroscopic diagrams of pure LAFT and SD systems. B. Infrared spectroscopic diagrams of Polymers.
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Table 4 e Selective IR peak intensities for pure LAFT and SD systems.
IR frequencies Formulation codes
LAFT
(unit e cm1)
LF1 SD
(unit- cm1)
LF4 SD
(unit e cm1)
LF7 SD
(unit e cm1)
LF10 SD
(unit e cm1)
aCeH (Stretching) 3324.32 3385.48 3408.99 3400.80 2913.25
CH2 3016.48 Broadening Broadening Broadening Broadening
Alkane stretch 2853.73 Broadening Broadening Broadening Broadening
CaO 1738.2 1737.1 1736.36 1731.75 1731.0
CaOeNH 1635.90 1602.19 1607.1 1598.90 1614.15
SaO 1041.78 1078.46 1111.13 1110.72 1123.38
CeS 729.57 714.02 714.02 713.56 716.78
aCeH (bending) 877 841.65 841.33 841.16 841.98
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 9 2e1 0 6100donating groups of LAFT and the proton accepting groups in
the Soluplus. IR spectra of used polymer and surfactant are
shown in Fig. 4B. Also, the IR peak intensities for selective
functional groups are represented in Table 4.
3.4.4. SEM Micrographs
Surface micrographs of prepared SD and pure LAFT were
determined using SEM technique. The SEM micrograph of
pure LAFT it observed large crystalline forms of drug ag-
glomerates with ordered shape and size Fig. 5(A). SEM of SDFig. 5 e SEM images of Pure LAFT (A)prepared using interaction of drug and polymer chains at
micro level. The particle size of combined matrix showed
marked decrease in size. The surface characteristics of SD
show rough disordered and intact structures, which subse-
quently help to dissolve drug when comes in contact with
aqueous fluid. However, in SD systems presence of relatively
rough surface, suggest that hydrophilic polymer and surfac-
tant were spread uniformly on the surface of the drug also
(Fig. 5BeE). The LAFT SD appeared to be agglomerated with
rough surface owing to the miscibility of drug into polymer., LF1 (B), LF4 (C), LF7 (D), LF10 (E).
Fig. 6 e A. Raman spectra of LF1, LF4, LF7, LF10. B. Raman
image of LF4.
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With Raman spectroscopy, a laser photon is scattered by
sample molecule and loses (or gains) energy during the pro-
cess. The amount of energy lost is seen as a change in energy
(wavelength) of the irradiating photon. This energy loss ischaracteristic for a particular bond in a molecule. The in-
tensity of spectral features in solution is directly proportional
to the concentration of the particular species as shown in
Fig. 6A. Raman spectra are generally robust to temperature
changes. Raman spectroscopy and its mapping technique are
useful tools to evaluate crystal and amorphous states,
including discrimination of crystalline diastereomer-pairs in
solid dispersions as shown in Fig. 6B. In addition, by describing
the distribution of the drug and the carrier, it could be guessed
how drug crystals become amorphous during preparation
from the point of view of the distribution of the amorphous
form of the drug substance and the carrier. It confirms the
presence of drug in amorphous form in SD and its uniform
distribution [35]. Images of the amorphous regions in SDs
described by the width at half maximum around 1400 and
1500 cm1 (green area was thought to be amorphous drugs).
3.4.6. AFM Characterisation
Fractured fresh extrudate with smooth surfaces are used for
microscopic investigations using AFM. Fracture surfaces were
generated at determined fracture points on the outer surfaces
of the extrudates. All extrudates had the form of transparent
cylindrical rods, 2 and 3.5 cm long and of 0.5 cm width were
selected, and placed on a sheet of paper. The freshly fractured
extrudatesweremounted on an optical glass slide by use of a 2
component epoxy resin, which hardened within w5 min.
Before the hardening reaction had been completed the extru-
date orientation was corrected to get the fracture surface as
horizontal as possible. This step is mandatory to enable non-
destructive imaging and automated sample changing within
Atomic Force Microscope operations [36]. Freshly fractured
extrudates on microscopic glass slides were mounted on the
micrometre positioning stage of a Dimension Icon AFM. Be-
tween 10 and 25 regions per sample were programmed to be
automatically characterized using the software routine “pro-
grammed move” in Tapping Mode. Height, phase, and ampli-
tude images were collected simultaneously, using etched
silicon cantilevers with a nominal spring constant of
k ¼ 40e100 N/m (JEOL AFM Probes). The typical free vibration
amplitude was in the range of A ¼ 80 nm, the images were
recorded with set-point amplitudes corresponding to 60e70%
of the free amplitude. Image areas of 10  10 mm were recor-
ded at a resolution of 1024  1024 pixels. All data were batch-
processed using Scanning Probe Image Processor (SPIP 5.1.1).
Height data were plane-corrected by applying a 3rd order
polynomial fit [37]. Molecular fracture roughness data as dis-
played in Fig. 7A, consist of image A and B shows cross
sectional surface roughness calculated from at least 10 images
on each sample. The 3D surface image of LF4 showed in image
C, which gives morphological surface interactions in detail.
The roughness parameters reflect the % variationwith respect
to the topographymeanheight,which is shown in imageD and
E. It indicates from the AFM analysis that there is high level of
surface interaction and amorphousization of drug inside
polymer matrix observed in extrudes. Fig. 7(B) indicates pat-
terns of AFM images of LF1 (F), LF7 (G) and LF10 (H) extrudes.
3.4.7. Molecular dynamic simulation studies
After energy minimization of drug and polymer strong
hydrogen bonding interactions were identified. The stable
Fig. 7 e A AFMmicroscopic image A (LF4), B (LF4 cross sectional), C (LF4 3D surface), D (% area graph) and E (% surface graph).
B AFM microscopic images of F (LF1), G (LF7) and H (LF10).
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MD simulation dynamics was started. The minimum inter-
action area from centroid was kept at 4 A to identify the
possible interactions. The energy for stretching, bending,
rotational, translational, torsional kinetic energies was
calculated during this simulation process. The energy of
combined system was found to be less than the addition of
energies of individual molecules, which signifies the
improved stability of SD formulation. Hydrogen bonding
interaction formed with the hydroxyl group of polymers with
chlorine group of LAFT. Interactions are formed between the
amine group of drug molecule and carbonyl groups of poly-
mers. In both the polymers drug entrapment and interaction
was favorable. Both hydroxyl and chlorine group within the
LAFT molecule could form strong hydrogen bonds with the
monomer of both polymers, which signified by the optimal
distance between the H-bond donor and acceptor. MD-
simulation studies revealed the possible drugepolymer in-
teractions. The effect of PEG 400, Lutrol F127 and Lutrol F68 on
the interaction between LAFT along with Soluplus was found
to be favorable. The stable conformations obtained aftermolecular dynamic simulation showed different geometric
arrangement of the molecules. The most stable was fount be
Fig. 8(B) with lowest energy and highest bonding interaction
between drug and polymer.
3.4.8. 1He COSY NMR investigations
Cross-peaks between all of the protons within a coupling
network were observed at protons range of d 3.3e4.5 ppm
with highest number. A small mixing time yields COSY
spectra at d 5.5 ppm. A large mixing time reveals cross-peaks
between protons further away in the coupling network at
d 6.5, 7, 7.5, and 8 ppm are observed. The physical stability of
the solid-state drug in amorphous dispersions with amor-
phous molecular mobility and drug-excipient miscibility was
well illustrated by 1HeCOSY NMR studies. It is shown in Fig. 9
that there is protoneproton coupling observed at various
points of resonance which clearly indicates high level of
molecular mixing between drug and polymer carrier [38]. The
entire resonance peaks specific for drug and carrier were
observed with coupling shifts between due proton
resonances.
Fig. 8 e MD simulation conformations of LAFT-Soluplus-PEG 400 (A), LAFT-Soluplus-Lutrol F127 (B), LAFT-Soluplus-Lutrol
F68 (C), LAFT-Soluplus (D).
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Higher apparent drug solubility and improved dissolution
profiles are attributed to the amorphous nature of LAFT in SDFig. 9 e 1H COSY NMR spectrsystem where LAFT is molecularly dispersed in the polymer
matrix. SD of LAFT showed disordered morphology. Lattice
energy of SD system is due to short-range intermolecular
interaction in amorphous system. When drug in SD dissolvesa of LF4 SD formulation.
Fig. 10 e A. In vitro release of pure LAFT, Lumefec and SD
systems in buffer of pH-1.2 [mean ± SD (n [ 3)]. B. In vitro
release of pure LAFT, Lumefec and SD systems in distilled
water [mean ± SD (n [ 3)].
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 9 2e1 0 6104then change in lattice energy not destructed by the drug itself
so the dissolution rate improved. While, in crystalline form
lattice energy has to be destructed for the drug to get dissolve.
Hence we don’t observe improved dissolution by simple
physical mixing of drug and polymer. Dissolution profiles of
various SD are as shown in Fig. 10A and B. The dissolution of
the SD with Soluplus (LF1 ¼ 100.45%, LF4 ¼ 110.84%,
LF7 ¼ 95.78%, LF10 ¼ 84.69%, at the end of T60 min) was
approximately 11.46, 12.58, 10.22, 9.67 fold higher than pure
LAFT respectively. The dissolution of the SD in water
(LF1 ¼ 65.42%, LF4 ¼ 75.89%, LF7 ¼ 54.78%, LF10 ¼ 50.21% at
T60 min) were approximately 15.87, 18.41, 13.29, 12.18 fold
than pure LAFT. The marketed tablet Lafumec dissolution
studies also carried out which is found to be inferior in terms
of dissolution as compared to prepared SD. Dissolution of the
drug in Soluplus alone is governed by the carrier, whereas inTable 5 e Order of drug release of SD systems determined by t
Formulation codes Zero order (r) First order (r) H
LF1 0.6932 0.849
LF4 0.5247 0.905
LF7 0.5326 0.954
LF10 0.6577 0.942the case of Soluplus e surfactant systems, the dissolution
rate is governed by solubilization of the polymer to create a
hydrotropic environment for the insoluble drug. It was
observed that of the Soluplus e surfactant SD dissolved
rapidly. The high dissolution rate of LAFT from the Soluplus-
PEG 400, Soluplus-Lutrol F127 and Soluplus-Lutrol F68
dispersion is believed to be due to the drugepolymer molec-
ular intermixing at micro level. The aqueous solubility and
dissolution rate of prepared SD was also significantly
enhanced. In comparison to pure LAFT, the dissolution rate of
physicalmixtureswas slightly increased probably because the
hydrophilic polymer scan wet the surface of drug particles
and acts to solubilize them. The dissolution of extrudates was
markedly enhanced with total release occurring within
20 min. This clearly shows that are markable improvement in
dissolution performance was achieved by HME [39]. From the
dissolution profiles it is evident that HME processing can be
employed for the manufacture of LAFT immediate release SD
by processing polymer-surfactant combination. The preferred
dissolution patterns can be achieved through the drug loading
percentage and the extrusion process. The extrusion appeared
to be an effective approach for the development of diffusion
controlled SD of LAFT.
3.5.1. Drug release kinetic evaluation
Drug release profiles of the optimized LAFT SD are evaluated
during dissolution studies. LAFT-SD had shown drug release
of 98e104% at the end of 20 min while pure drug (used as
reference) released 4e6% at the end of 1 h. The observed
transformation in the release pattern strongly indicated the
influence of surfactants along with Soluplus on the dissolu-
tion rate enhancement from the SD. The release data was
fitted into various kinetic models like zero order, first order,
Higuchi-matrix, KorsemeyerePeppas, and HixsoneCrowell in
order to establish the mechanism of drug release from pre-
pared SD Table 5. SD was found to follow Higuchi release
mechanism (r2 ¼ 0.9973e0.9996) and demonstrated the im-
mediate drug release (n < 0.05) mechanism, which is signifi-
cant with the exposition of more surface area of drug inside
SD to the dissolution medium [40].3.6. Stability on storage
SD is thermodynamically metastable system that favours the
conversion of amorphous form in the crystalline form under
storage [41]. To evaluate the physical state of the drug, the
systems were characterized by XRD and DSC after storage for
6 months. The systems were stable during a 6-month period.
In the case of SD, no substantial recrystallization was
observed by DSC or XRD over the 6 months storage suggesting
LAFT is more stable in this formulation. This may be becausehe regression coefficients.
iguchi (r) HixoneCrowell (r) KrosmeyerePeppas (r)
0.9973 0.7190 0.2289
0.9993 0.7378 0.1193
0.9993 0.7007 0.8875
0.9924 0.6945 0.8685
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 9 2e1 0 6 105SOL can engage in more extensive hydrogen bonding with
LAFT and used surfactants, resulting in less molecular
mobility. In addition, there were no significant variations in
content of drug and related substances or in dissolution pro-
files after storage. Taken together, these results imply that SD
formulations are stable over the storage period and that the
small quantity of LAFT microcrystals (approximately 2.3%)
found after storage has little effect on the stability of the SD.
The enhanced physical stability of the SD upon storage is
attributed to drugepolymer interactions and solubilization
effects of the polymer. Soluplus-surfactant systems had
strong intermolecular interactions, particularly hydrogen
bonding between amorphous LAFT and the polymer. These
might further reduce the molecular mobility and retarded
recrystallization during storage. The stability studies of solid
dispersion revealed insignificant changes in the stability pa-
rameters (p-value<0.05) when kept at 40 C/75% RH, and room
temperature respectively at the end of six months. The
percent drug entrapments found in the range of 97.4  1.8%e
99.2  1.5% in different LAFT SD systems were noted during
stability studies. All determinations are performed by using
HPLC are mean  SD (n ¼ 3).4. Conclusion
In the current study it was clearly demonstrated that LAFT
immediate release SD formulation can be effectively pro-
duced by processing via HME with enhanced solubility and
dissolution rate. Novel polymeresurfactant combinations
were optimised and stable SD systems were developed
successfully. Utilization of Soluplus along with suitable
surfactants offers excellent possibilities to develop stable
amorphous solid dispersion. Selective use of surfactants
with low concentrations improves process workability, in-
crease melt viscosity with torque reduction, reduce Tg of
blend, augments quality of extrudes, reduce residence time
of extrusion. The study revealed the importance of suitable
carrier and processing technique selection are critical pa-
rameters during HME. AFM analyses revealed microscopic
surface interaction between drug and polymer. MD simula-
tion studies revealed possible molecular interaction be-
tween drug-polymer. 1H COSY NMR study confirms the
molecular mobility and proton-coupling shift at particular
resonance. Furthermore, this LAFT-incorporated solid
dispersion gave higher dissolution and solubility values
compared to the commercial product and pure LAFT pow-
der, indicating that it might improve the oral bioavailability
of LAFT in rats.
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